CD276 immune expression and prognosis in pan-cancer
10.12007/j.issn.0258-4646.2023.12.009
- VernacularTitle:CD276在泛癌中的免疫表达及预后
- Author:
Guiqian ZHANG
1
,
2
,
3
,
4
;
Ning WANG
;
Yao RONG
;
Mingzheng TANG
;
Hui CAI
Author Information
1. 甘肃中医药大学第一临床医学院,兰州 730000
2. 甘肃省人民医院临床普外中心,兰州 730000
3. 国家卫生健康委胃肠肿瘤诊治重点实验室,甘肃省人民医院,兰州 730000
4. 甘肃省外科肿瘤分子诊断与精准治疗重点实验室,甘肃省人民医院, 兰州 730000
- Keywords:
CD276;
tumor microenvironment;
immunity;
prognosis;
pan-cancer
- From:
Journal of China Medical University
2023;52(12):1106-1112,1118
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of CD276 in pan-cancer,its effect on patient prognosis,and its mechanism of action.Methods TCGA and GTEx databases were used to study the differential expression of CD276 in tumor and normal tissues;R language was used to analyze the effects of CD276 on the prognosis of patients with pan-cancer,the tumor microenvironment,the tumor mutation burden,and microsatellite instability;the correlation between the expression of CD276 in tumor tissues and the tumor immune cell infil-tration was further examined;the biological function of CD276 was analyzed using Gene Set Enrichment Analysis(GSEA);and finally,real-time PCR was used to validate the expression of CD276 in tumors in vitro.Results A statistical difference in CD276 expression was detected between tumor and normal tissues(P<0.05).CD276 affects tumor prognosis and is strongly associated with the tumor microenvi-ronment,tumor mutational burden,microsatellite instability,and tumor immune cell infiltration.Conclusion Comprehensive pan-cancer analysis identified CD276 as a biomarker for immune infiltration and poor cancer prognosis,which can be used as a novel immunomodula-tory target for the development of immunotherapeutically-targeted drugs,providing new ideas for tumor therapy.
